These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38916717)

  • 1. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
    Fritsch A; Meyer M; Blaustein RO; Trujillo ME; Kauh E; Roessig L; Boettcher M; Becker C
    Clin Pharmacokinet; 2024 Jun; 63(6):751-771. PubMed ID: 38916717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
    Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
    J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
    Trujillo ME; Ayalasomayajula S; Blaustein RO; Gheyas F
    Clin Transl Sci; 2023 Dec; 16(12):2458-2466. PubMed ID: 37997225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
    Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
    Senni M; Alemayehu WG; Sim D; Edelmann F; Butler J; Ezekowitz J; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Westerhout CM; McMullan C; Armstrong PW;
    Eur J Heart Fail; 2022 Sep; 24(9):1614-1622. PubMed ID: 35791083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
    N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
    Boettcher M; Gerisch M; Lobmeyer M; Besche N; Thomas D; Gerrits M; Lemmen J; Mueck W; Radtke M; Becker C
    Clin Pharmacokinet; 2020 Nov; 59(11):1407-1418. PubMed ID: 32458378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
    Pieske B; Pieske-Kraigher E; Lam CSP; Melenovský V; Sliwa K; Lopatin Y; Arango JL; Bahit MC; O'Connor CM; Patel MJ; Roessig L; Morris DA; Kropf M; Westerhout CM; Zheng Y; Armstrong PW;
    Eur J Heart Fail; 2023 Jul; 25(7):1012-1021. PubMed ID: 36994634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).
    Xia J; Hui N; Tian L; Liang C; Zhang J; Liu J; Wang J; Ren X; Xie X; Wang K
    Biomed Pharmacother; 2022 May; 149():112894. PubMed ID: 35367763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
    Campbell N; Kalabalik-Hoganson J; Frey K
    Ann Pharmacother; 2022 May; 56(5):600-608. PubMed ID: 34431706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
    Boettcher M; Thomas D; Mueck W; Loewen S; Arens E; Yoshikawa K; Becker C
    Eur J Clin Pharmacol; 2021 Apr; 77(4):527-537. PubMed ID: 33125516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.